Effect of pentoxifylline on lung inflammation and gas exchange in a sepsis-induced acute lung injury model.
Experimental models of sepsis-induced pulmonary alterations are important for the study of pathogenesis and for potential intervention therapies. The objective of the present study was to characterize lung dysfunction (low PaO2 and high PaCO2, and increased cellular infiltration, protein extravasation, and malondialdehyde (MDA) production assessed in bronchoalveolar lavage) in a sepsis model consisting of intraperitoneal (ip) injection of Escherichia coli and the protective effects of pentoxifylline (PTX). Male Wistar rats (weighing between 270 and 350 g) were injected ip with 10(7) or 10(9) CFU/100 g body weight or saline and samples were collected 2, 6, 12, and 24 h later (N = 5 each group). PaO2, PaCO2 and pH were measured in blood, and cellular influx, protein extravasation and MDA concentration were measured in bronchoalveolar lavage. In a second set of experiments either PTX or saline was administered 1 h prior to E. coli ip injection (N = 5 each group) and the animals were observed for 6 h. Injection of 10(7) or 10(9) CFU/100 g body weight of E. coli induced acidosis, hypoxemia, and hypercapnia. An increased (P < 0.05) cell influx was observed in bronchoalveolar lavage, with a predominance of neutrophils. Total protein and MDA concentrations were also higher (P < 0.05) in the septic groups compared to control. A higher tumor necrosis factor-alpha (P < 0.05) concentration was also found in these animals. Changes in all parameters were more pronounced with the higher bacterial inoculum. PTX administered prior to sepsis reduced (P < 0.05) most functional alterations. These data show that an E. coli ip inoculum is a good model for the induction of lung dysfunction in sepsis, and suitable for studies of therapeutic interventions.
Oliveira-Junior
I S
IS
Divisão de Moléstias Infecciosas, Universidade Federal de São Paulo, Brasil.
Brunialti
M K C
MK
Koh
I H J
IH
Junqueira
V B C
VB
Salomão
R
R
D000208:Acute Disease; D000818:Animals; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy; D018836:Inflammation Mediators / Q000097:blood; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010431:Pentoxifylline / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011659:Pulmonary Gas Exchange / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology
D018836:Inflammation Mediators; D010726:Phosphodiesterase Inhibitors; D008315:Malondialdehyde; D010431:Pentoxifylline